Some people lose part of their hearing to a pill bottle and never once suspect it. The bottle came with a doctor's signature. The loss came with no sound at all: a kettle that seemed thinner than it used to, a faint whistle at bedtime they blamed on stress, a daughter's voice that quietly started needing a second try. Years later, in an audiologist's chair, they talk about the concerts of their twenties. Nobody mentions the three weeks of intravenous antibiotics after a bad infection, or the summer of high-dose aspirin for a ruined back. Why would they? Medicine is the thing that fixes you.
The word for this is ototoxicity, and it names one of the most common and least talked-about ways an ear gets hurt. It is not a rare side effect buried in fine print. It is a known property of several drug families that millions of people take every year, often for very good reasons. Understanding it will not make you afraid of your prescriptions. It will make you a better witness to your own ears, which is the one thing nobody else can be for you.
The word nobody says at the pharmacy counter
"Ototoxic" simply means poisonous to the ear. Clinicians have known about it since the earliest antibiotics: streptomycin, the first drug that could cure tuberculosis, also left some patients deaf or dizzy. The list has grown since. The main families are aminoglycoside antibiotics such as gentamicin, tobramycin and amikacin; platinum-based chemotherapy, especially cisplatin; loop diuretics like furosemide; quinine and its relatives; and salicylates, the chemical family that includes ordinary aspirin, along with other anti-inflammatories at high doses.
That list sounds alarming until you notice what it has in common. These are mostly drugs for serious situations: dangerous infections, cancer, heart failure. The decision to use them is usually the right one. The problem is not that they exist. The problem is that the ear's complaint is silent, slow, and easy to file under "getting older."
How a drug reaches a hair cell
Your inner ear hears through roughly fifteen thousand hair cells per cochlea, each crowned with a bundle of stiff filaments that bend when sound pushes fluid past them. Those cells do not regenerate in humans. When one dies, its frequency goes with it.
Aminoglycosides are blunt about it. They circulate in the bloodstream, pass into the fluid of the inner ear, and enter hair cells, in part through the very channels that open when the bundle bends to detect sound. Inside, they trigger a surge of reactive oxygen species, the unstable molecules behind oxidative stress elsewhere in the body, and the cell is pushed into programmed death. The cells at the base of the cochlea, which encode the highest pitches, are the most vulnerable. That is why ototoxic hearing loss almost always begins above the range of ordinary speech, where you would never notice it in conversation. A small number of people carry a mitochondrial gene variant that makes their hair cells dramatically more sensitive to these drugs; for them, a single standard course can be enough.
Cisplatin works through a similar oxidative pathway with an added cruelty: it lingers in cochlear tissue long after it has cleared from the rest of the body, so damage can accumulate across treatment cycles and continue after the last dose. This is why hearing monitoring is part of standard cancer care, and why a protective agent, sodium thiosulfate, has recently been approved to reduce hearing loss in children receiving cisplatin.
Loop diuretics take a different route. They act on the stria vascularis, the tissue that works as the cochlea's battery, maintaining the electrical charge hair cells need to signal. Dampen the battery and hearing drops. Restore it and hearing usually returns.
Reversible and not
That last point matters more than any list. Ototoxic effects fall into two broad kinds, and the difference between them is the difference between an uncomfortable fortnight and a permanent change.
Salicylate ototoxicity is the classic reversible case. At high doses, aspirin interferes with prestin, the motor protein that lets outer hair cells contract and amplify quiet sounds, and it also shifts activity in the auditory brain itself. The result is tinnitus and a mild, flat hearing loss that typically fades within days of the dose being reduced or stopped. Low-dose aspirin taken for the heart rarely does this; it is the anti-inflammatory doses, taken for pain over weeks, that tend to produce ringing. Quinine behaves much the same way. Loop diuretics, used alone and by mouth, mostly do too.
Aminoglycosides and cisplatin sit in the other category. Once the hair cell is gone, the frequency is gone, and the loss can keep progressing for a while after treatment ends. Risk also compounds. A loop diuretic given alongside an aminoglycoside, or an aminoglycoside given to someone whose kidneys clear it slowly, raises the stakes considerably. Loud noise during treatment adds to the burden, because the same cells are already under stress.
None of this is a reason to refuse a drug. It is a reason to know which category you are in, and to ask.
Why tinnitus is usually the first messenger
Here is the piece most people get backwards. They assume hearing loss comes first and ringing follows. With ototoxic drugs it is often the reverse. A new or changed tinnitus, a high whistle that was not there last week, is frequently the earliest sign that the cochlea is struggling, and it can appear before a standard hearing test registers any change. Fullness in the ears, or unsteadiness when you turn your head, can carry the same message, since the balance organs share the inner ear's fluid and the same vulnerable cells.
This is why the ear's silence is such a trap. The highest frequencies go first, and routine audiometry stops at eight thousand hertz, below where early damage begins. Specialized high-frequency testing can catch it sooner, but you have to know to ask. Meanwhile, tinnitus is dismissable in a way a rash is not. You are in a hospital bed, or mid-chemotherapy, or frightened about your heart. A faint tone at night does not feel like the thing to raise. So it goes unraised, and the window in which a dose could have been adjusted or an alternative considered closes quietly.
The baseline problem
The deepest difficulty with ototoxicity is not biological. It is that almost nobody knows what their hearing was before. Without a starting point, a slight shift is indistinguishable from the slow slope of age, and the question "has anything changed?" cannot honestly be answered from memory. Professional guidelines for ototoxicity monitoring are built on exactly this insight: test before the first dose, test again at intervals, and compare. A result that would mean nothing on its own becomes meaningful when it is a change from you.
That idea is portable. It belongs to anyone, not only to cancer patients.
Your next moves
- Before starting any new long-term medication, ask one question out loud: "Is this known to affect hearing or cause ringing?" Prescribers answer it readily but rarely volunteer it. If the answer is yes, ask whether a baseline hearing check makes sense and whether high-frequency testing is available.
- If you are prescribed an aminoglycoside antibiotic, cisplatin, or an intravenous loop diuretic, request hearing monitoring explicitly. It is standard in good care, but on a busy ward it can be forgotten. Ask that it be written into your plan.
- Start a plain note on your phone today titled "Ears." Write what your tinnitus sounds like right now, if you have any, and how loud a normal day feels. Add a line whenever you start or stop a medication. Two sentences a month gives a clinician something real to compare against.
- Report new ringing, fullness, or unsteadiness within a day, not at the next appointment. Use the word "ototoxic" when you do; it tells the team exactly what you are worried about. Never stop a prescribed medication on your own. Dose changes and alternatives are decisions for the person who prescribed it.
- Protect the ears you are already stressing. During any course of a potentially ototoxic drug, avoid loud environments or wear hearing protection in them, since noise and drug damage compound in the same cells.
Where Audra fits
Everything above comes down to one quiet discipline: knowing your own starting line and checking back against it. Audra was built for that. Its free at-home pure-tone screening gives you a baseline you can take before a new prescription and repeat afterwards, entirely on your device, with a hearing wellness history that shows change over time instead of asking your memory to guess. If a medication has left you with a tone that will not leave, its personalized notched-sound enrichment is shaped around your own tinnitus pitch for the hours when the ringing is loudest. It is a screening and a companion, not a diagnosis, and it will never replace the audiologist your care team can arrange. But it can make you the kind of patient who notices early, which is the whole game. You can start at audra.lumenlabs.works.